Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fujian Green Pine Co., Ltd. (300132.SZ)
Jianyang, CN
Fujian Green Pine Co., Ltd. focuses on the entire lifecycle of turpentine derivatives, from initial research and development through to manufacturing and sales. Their extensive product line encompasses a wide array of chemical compounds, such as synthetic camphor, isobornyl acetate, camphene, borneol flakes, para cymene, pinene, dipentene, isoborneol, both crystalline and anhydrous sodium acetate, isobornyl (meth) acrylate, myrcene, benzyl acetate, QS keton, and various solvent oils. These products find diverse applications across sectors including flavorings, fragrances, pharmaceuticals, personal care items, cleaning solutions, and paints and coatings. The company maintains a global presence, conducting business across Asia, Europe, North America, South America, Oceania, and Africa. Established in 1958, the firm is headquartered in Jianyang, China, and adopted its current name, Fujian Green Pine Co., Ltd., in May 2009, having previously been known as Jianyang City Green Pine Chemical Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.08% | -7.21% | +1.56% | +5.47% | +4.94% | -2.53% | +57.22% | +47.65% | -62.73% | +18.25% | -7.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+14.4% ★ Q1'26: +14.6% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+181.8% ★ Q1'26: +1,057.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+10.2% ★ Q1'26: +19.3% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+8.5% Q1'26: +5.4% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+16.9% ★ Q1'26: +12.6% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-1.1% ★ Q1'26: -0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.74× ★ Q1'26: 0.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.42B
est: 1.35B (+5.1%)
|
2.91B
est: 2.66B (+9.5%)
|
3.86B
est: 3.86B (+0.2%)
|
3.63B
est.
|
3.69B
est: 2.92B (+26.7%)
|
1.97B
est: 1.90B (+3.5%)
|
2.92B
est: 1.90B (+53.3%)
|
1.94B
est: 1.94B (+0.2%)
|
2.22B
est: 2.19B (+1.1%)
|
2.56B
2.50B – 2.61B
+16.5% YoY
|
2.92B
2.80B – 3.03B
+14.0% YoY
|
3.22B
3.15B – 3.29B
+10.5% YoY
|
| EBITDA |
502.77M
est: 57.12M (+780.2%)
|
651.69M
est: 112.11M (+481.3%)
|
682.61M
est: 162.88M (+319.1%)
|
153.09M
est.
|
-763.04M
est: 123.05M (-720.1%)
|
23.25M
est: 871.15M (-97.3%)
|
-625.26M
est: 871.15M (-171.8%)
|
154.14M
est: 886.02M (-82.6%)
|
295.28M
est: 1.00B (-70.6%)
|
1.17B
1.15B – 1.19B
+16.5% YoY
|
1.33B
1.28B – 1.39B
+14.0% YoY
|
1.47B
1.44B – 1.50B
+10.5% YoY
|
| EBIT |
471.10M
est: -25.27M (+1,964.0%)
|
583.59M
est: -49.61M (+1,276.5%)
|
588.85M
est: -72.07M (+917.0%)
|
-67.74M
est.
|
-870.49M
est: -54.45M (-1,498.7%)
|
-62.67M
est: 776.29M (-108.1%)
|
-740.03M
est: 776.29M (-195.3%)
|
82.50M
est: 789.53M (-89.6%)
|
188.51M
est: 894.95M (-78.9%)
|
1.04B
1.02B – 1.06B
+16.5% YoY
|
1.19B
1.14B – 1.24B
+14.0% YoY
|
1.31B
1.29B – 1.34B
+10.5% YoY
|
| Net Income |
400.35M
est: 534.23M (-25.1%)
|
453.16M
est: 489.88M (-7.5%)
|
460.80M
est: 487.61M (-5.5%)
|
-826.55M
est.
|
-911.67M
est: -685.43M (-33.0%)
|
-68.34M
est: 74.3K (-92,086.4%)
|
-742.42M
est: 74.3K (-999,387.6%)
|
54.68M
est: 34.90M (+56.7%)
|
153.23M
est: 137.12M (+11.7%)
|
174.52M
169.73M – 179.31M
+27.3% YoY
|
211.54M
203.95M – 224.87M
+21.2% YoY
|
249.31M
242.48M – 256.15M
+17.9% YoY
|
| SGA |
55.46M
est: 38.48M (+44.1%)
|
177.69M
est: 75.53M (+135.3%)
|
239.51M
est: 109.73M (+118.3%)
|
103.13M
est.
|
241.26M
est: 82.90M (+191.0%)
|
192.76M
est: 137.92M (+39.8%)
|
241.38M
est: 137.92M (+75.0%)
|
188.69M
est: 140.28M (+34.5%)
|
42.34M
est: 159.01M (-73.4%)
|
185.20M
181.29M – 189.11M
+16.5% YoY
|
211.21M
202.70M – 219.73M
+14.0% YoY
|
233.31M
228.39M – 238.23M
+10.5% YoY
|
| EPS |
1.04
est: 1.06 (-1.9%)
|
0.96
est: 0.97 (-1.2%)
|
0.89
est: 0.97 (-8.0%)
|
-1.64
est.
|
-1.76
est: -1.36 (-29.4%)
|
-0.13
est: 0.00 (-87,348.3%)
|
-1.44
est: 0.00 (-966,543.0%)
|
0.11
est: 0.07 (+57.1%)
|
0.31
est: 0.28 (+12.7%)
|
0.35
0.34 – 0.36
+27.3% YoY
|
0.43
0.41 – 0.45
+22.9% YoY
|
0.50
0.49 – 0.51
+16.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 1.7K | 0.26% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 742.15 | 0.48% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 82.6K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 132.85 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 400.43 | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 215.19 | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 94.79 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 10.92 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 3.59 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 1.71 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lan Wu | Accounting Supervisor | — | — |
| Qihui Luo | Vice President & Board Secretary | — | male |
| Ruzheng Ouyang | Executive Vice President | — | male |
| Yucong Wang | Financial Director | — | male |
| Yuecong Lin | Vice President & Director | — | male |
| Zhanhua Fan | Chairman & President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300132.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
